Dihydropyrimidine Dehydrogenase (DPYD)
Also known as: DPYD
Use
This test predicts the risk of dose-related toxicity to 5-fluorouracil (5-FU) therapy. 5-FU is a commonly used chemotherapeutic drug, particularly for colorectal adenocarcinoma. Variants in the DPYD gene can lead to reduced catabolism of 5-FU, resulting in increased drug concentrations and risk of severe toxicity, potentially causing hematologic, gastrointestinal, and dermatologic complications. A decrease in dihydropyrimidine dehydrogenase enzymatic activity may lead to increased risk for grade III-IV toxicity, affecting approximately 16% of patients. The test helps in identifying reduced 5-FU catabolism and related toxicity complications due to genetic variations.
Special Instructions
Not provided.
Limitations
This test detects only the targeted DPYD variants. Diagnostic errors may occur due to rare sequence variations. 5-FU drug metabolism, efficacy, and toxicity risks may be influenced by factors not evaluated by this test. Genotyping does not replace the need for therapeutic drug monitoring or clinical observation. The test does not provide medication recommendations; any dosage adjustments should be made in consultation with a medical provider.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
DPYD
Gene
LOINC Codes
- 31208-2 - Specimen source
- 79719-1 - DPYD gene prod met act imp Bld/T-Imp
- 11526-1 - Pathology study
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B)
Causes for Rejection
Plasma or serum. Heparinized specimens. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | 1 month |
Other tests from different labs that may be relevant